NantWorks Release: NantOmics To Present Clinical Trial Data On The Characterization Of Molecular Profiles Of Metastatic Triple Negative Breast Cancer With GPS Cancer™ At ASCO 2017 Annual Meeting

CHICAGO--(BUSINESS WIRE)--NantWorks, LLC today announced that its affiliate company, NantOmics, LLC, the leader in molecular diagnostics and a member of the NantWorks ecosystem of families, will present findings on comprehensive omics profiling, GPS Cancer, in patients with metastatic triple negative breast cancer (TNBC) at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, an event bringing together 30,000 oncology professionals June 2-6, 2017 at McCormick Place in Chicago, Illinois. Patients involved in the study were enrolled in a clinical trial, Intensive Trial of OMics in Cancer, based in Seattle. NantWorks will be exhibiting at booth #19135 during the event.

“GPS Cancer is a personalized molecular profile that is a decision support tool for oncologists to gain insights into cancer therapy before treatment in initiated,” said Patrick Soon-Shiong, MD, founder of NantWorks. “We’ve seen how successful GPS Cancer has proven to be since the commercial launch at ASCO 2016. Now, a year later, we’re looking forward to presenting clinical data on the insights GPS Cancer can provide into underlying treatment resistance and disease progression beginning with metastatic triple negative breast cancer.”

GPS Cancer, a unique molecular profile performed in the CLIA-certified, CAP-accredited laboratories of NantOmics, integrates whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics to provide oncologists with a comprehensive molecular profile of a patient’s cancer to inform personalized treatment strategies. GPS Cancer provides critical insights based on the unique biology of a patient’s tumor—from the DNA to the RNA to the protein. The richness of this information helps doctors to build potentially more effective treatment plans based on current drugs and active clinical trials, while enabling cancer researchers to design new clinical trials that harness the potential of the immune system.

Presentation Details
Investigating tumoral and temporal heterogeneity through comprehensive -omics profiling in patients with metastatic triple negative breast cancer, Abstract #1093

Presentation Summary
Patients involved in this study were enrolled in the “Intensive Trial of OMics in Cancer” and had been diagnosed with metastatic triple negative breast cancer (TNBC). Multiple biopsies were performed and samples were collected for GPS Cancer profiling. A total of 74 biopsies were analyzed from 17 patients taken at various points over the span of two years on trial and over eight years before recruitment. GPS Cancer was used to detect somatic alterations, measure mutational burdens, and estimate expression profiles of both transcripts and proteins. It was observed up to a 10-fold difference in the magnitude of mutational burden between patients. GPS Cancer provided detailed characterizations of the molecular profiles of metastatic TNBC patients which resulted in sharing insights into underlying treatment resistance and disease progression, which is the foundation for the molecularly informed QUILT program for combination therapy.

About NantOmics
NantOmics, a member of the NantWorks ecosystem of companies, delivers molecular diagnostic capabilities with the intent of providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular diagnostics company to pioneer an integrated approach to unearthing the genomic and proteomic variances that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient and following identified variances through from DNA to RNA to protein to drug. NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time, and correlating proteomic pathway analysis with quantitative multi-plexed protein expression analysis from the same micro-dissected tumor sample used for genomic analysis. For more information please visit www.nantomics.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

About NantWorks
NantWorks, LLC, founded by renowned physician scientist and inventor of the first human nanoparticle chemotherapeutic agent Abraxane^®, Dr. Patrick Soon-Shiong, is the umbrella organization for the following entities: NantHealth, NantMobileHealth, NantOmics, NantBio, NantCell, NantPharma, NantCapital and NantCloud. Fact-based and solution-driven, each of NantWorks’ division entities operates at the nexus of innovation and infrastructure. The core mission of NantWorks is convergence and a systems approach to human biology: to develop and deliver a diverse range of technologies that accelerates innovation, broaden the scope of scientific discovery, enhance ground-breaking research, and improve healthcare treatment for those in need. NantWorks is building an integrated fact-based, genomically and proteomically informed, personalized approach to the delivery of care and the development of next generation diagnostics and therapeutics for life threatening diseases such as Cancer, Infectious Diseases and Alzheimer’s. For more information please www.nantworks.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

About GPS Cancer™
GPS Cancer™ is a unique, molecular scan available through NantHealth. GPS Cancer integrates whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics through mass spectrometry, providing oncologists with a comprehensive molecular profile of a patient’s cancer and an assessment of protein pathway function to inform personalized treatment strategies. GPS Cancer scanning is conducted in CLIA-certified and CAP-accredited laboratories, and is a key enabler for Cancer Breakthroughs 2020, the world’s most comprehensive cancer collaborative initiative seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. For more information, visit www.gpscancer.com and www.cancerbreakthroughs2020.org.